TGFB1 and osteogenesis imperfecta: To translate these mechanistic findings, we conducted a phase I trial in adults with OI to evaluate the safety of fresolimumab, a human IgG4 κ monoclonal antibody that neutralizes all 3 TGF-β homodimers.